Danaher Co. (NYSE:DHR) Holdings Boosted by Raymond James & Associates

Raymond James & Associates raised its stake in Danaher Co. (NYSE:DHR) by 5.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,343,260 shares of the conglomerate’s stock after acquiring an additional 73,960 shares during the period. Raymond James & Associates owned 0.18% of Danaher worth $335,439,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Banco Santander S.A. acquired a new stake in Danaher in the third quarter worth $683,000. First Citizens Bank & Trust Co. increased its holdings in shares of Danaher by 0.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the period. Finally, Keybank National Association OH grew its position in Danaher by 0.5% in the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after purchasing an additional 2,567 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DHR has been the subject of several analyst reports. Bank of America boosted their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Robert W. Baird lifted their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday. TD Cowen upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, KeyCorp raised their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $270.00.

Danaher Price Performance

Shares of NYSE DHR traded up $0.78 during trading on Friday, hitting $246.58. The company had a trading volume of 2,710,446 shares, compared to its average volume of 2,710,897. The company has a market cap of $182.64 billion, a P/E ratio of 41.77, a PEG ratio of 3.78 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. The business’s 50-day moving average is $248.87 and its 200 day moving average is $231.08. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the firm earned $2.36 earnings per share. Danaher’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities research analysts predict that Danaher Co. will post 7.65 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were issued a $0.27 dividend. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders sold a total of 106,565 shares of company stock valued at $26,641,364 over the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.